Video: Reconstituting Valproic Acid (VPA) for Reprogramming

Donor Variability in Ex Vivo Human Tissue Studies: Challenge, Feature, or Translational Advantage

Explore how donor variability in ex vivo human tissue studies enhances translational research by providing insights into patient heterogeneity and improving drug discovery.

12 March 2026

REPROCELL Attends Japan-Maryland Night 2026

REPROCELL was honored to attend Japan-Maryland Night on Wednesday March 4th 2026  Maryland State, USA, hosted by the Embassy of Japan (in Washington DC).

06 March 2026

From StemRNA™ Clinical Seed Clone to GMP-Ready Cell Therapy Programs

Discover how REPROCELL’s StemRNA™ Clinical iPSC Seed Clones streamline the path to GMP-ready cell therapy, simplifying regulatory processes and enabling scalable, high-quality manufacturing.

27 February 2026

Preserving the Microenvironment-Advances in Ex Vivo Colonic Tissue Culture for IBD Drug Discovery

Advances in ex vivo colonic tissue culture preserve the microenvironment, enhancing IBD drug discovery by maintaining native tissue architecture and immune complexity for more predictive research models.

26 February 2026